PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes

NCT07527078 · Phase 3 · Recruiting

PHASEPhase 3
STATUSRecruiting
ENROLLMENT350
EST. COMPLETION2026-04-07

Conditions

Type 2 Diabetes (T2DM)

Interventions

GZR33 InjectionInsulin Degludec Injection (Tresiba®)

Study details

SPONSORGan & Lee Pharmaceuticals.
START DATE2026-04-07

Related company profiles

Gan & Lee Pharmaceuticals

603087.SS

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT07527078
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record